Published in Ann Surg Oncol on March 03, 2005
Proton Radiation for Resectable Carcinoma of the Pancreas (PC02) | NCT00763516
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer (2011) 1.32
Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther (2010) 1.21
The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol (2010) 1.09
Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg (2013) 1.01
Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol (2009) 0.99
Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int J Radiat Oncol Biol Phys (2007) 0.98
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg (2012) 0.96
Current status of adjuvant therapy for pancreatic cancer. Oncologist (2010) 0.93
Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol (2012) 0.86
Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford) (2009) 0.86
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol (2007) 0.86
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. Medicine (Baltimore) (2015) 0.84
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer (2015) 0.81
Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma. PLoS One (2016) 0.76
Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer. Korean J Hepatobiliary Pancreat Surg (2013) 0.75
A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. BMC Cancer (2016) 0.75
Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach? Cancers (Basel) (2011) 0.75
Histological and molecular markers for pancreatic adenocarcinoma: can they help us define which patients should receive it? Ann Surg Oncol (2005) 0.75
Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Medicine (Baltimore) (2015) 0.75
Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol (2016) 0.75
The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. Clin Oncol (R Coll Radiol) (2014) 0.75
Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer (2016) 0.75
Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett (2017) 0.75
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol (2013) 5.96
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Pneumatosis intestinalis in the adult: benign to life-threatening causes. AJR Am J Roentgenol (2007) 3.92
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
AGA Institute technical review on acute pancreatitis. Gastroenterology (2007) 3.18
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg (2003) 2.73
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol (2010) 2.46
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg (2004) 2.41
Clinical practice. Suspected appendicitis. N Engl J Med (2003) 2.38
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc (2003) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Dual-energy multidetector CT: how does it work, what can it tell us, and when can we use it in abdominopelvic imaging? Radiographics (2010) 2.27
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med (2009) 2.23
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. Oncology (Williston Park) (2011) 2.04
Does resident post graduate year influence the outcomes of inguinal hernia repair? Ann Surg (2005) 2.01
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96
Renal stone assessment with dual-energy multidetector CT and advanced postprocessing techniques: improved characterization of renal stone composition--pilot study. Radiology (2009) 1.90
Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med (2010) 1.89
Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology (2008) 1.87
Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. Chest (2007) 1.86
A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. Gastrointest Endosc (2006) 1.86
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg (2011) 1.82
Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle (2008) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology (2003) 1.73
Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol (2006) 1.70
Failure-to-pursue rescue: explaining excess mortality in elderly emergency general surgical patients with preexisting "do-not-resuscitate" orders. Ann Surg (2012) 1.67
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology (2013) 1.67
The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Gastrointestinal imaging: endoscopic ultrasound. Gastroenterology (2002) 1.64
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet (2012) 1.63
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg (2013) 1.58
MDCT of abdominal wall hernias: is there a role for valsalva's maneuver? AJR Am J Roentgenol (2005) 1.57
Locally advanced pancreatic cancer. J Clin Oncol (2005) 1.55
Outcome of endoscopic minor papillotomy in patients with symptomatic pancreas divisum. JOP (2004) 1.54
Resident education in the era of patient safety: a nationwide analysis of outcomes and complications in resident-assisted oncologic surgery. Ann Surg Oncol (2013) 1.52
Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol (2004) 1.52
Pancreatic FNA in 1000 cases: a comparison of imaging modalities. Gastrointest Endosc (2005) 1.52
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Peripherally administered CRF stimulates colonic motility via central CRF receptors and vagal pathways in conscious rats. Am J Physiol Regul Integr Comp Physiol (2005) 1.50
Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol (2003) 1.49
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park) (2010) 1.48
Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol (2006) 1.47
The impact of functional dependency on outcomes after complex general and vascular surgery. Ann Surg (2015) 1.45
Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology (2005) 1.44
Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44
Inguinal hernia: an old condition with new solutions. Ann Surg (2003) 1.44
Racial disparities in outcomes after appendectomy for acute appendicitis. Am J Surg (2011) 1.44
Hypervascular liver tumors: low tube voltage, high tube current multi-detector row CT for enhanced detection--phantom study. Radiology (2008) 1.44
ERCP during pregnancy. Am J Gastroenterol (2003) 1.41
Propofol for conscious sedation? Gastroenterology (2002) 1.41
Electroacupuncture at ST-36 accelerates colonic motility and transit in freely moving conscious rats. Am J Physiol Gastrointest Liver Physiol (2005) 1.40
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Gadolinium-enhanced CT angiography of endovascular stent-grafts. AJR Am J Roentgenol (2005) 1.39
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39